# Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

> **NCT06801015** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 30 (estimated)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Tirzepatide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06801015
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2028-01-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06801015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06801015, "Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06801015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*